Stock AnalizTrulieve Cannabis Corp. TRLV
Medicinal Chemicals and Botanical Products · data as of November 13, 2026
Trulieve Cannabis Corp. (TRLV) is a healthcare company listed in the US with a market value of about $1.9B. In the twelve months to September 30, 2026 it had revenue of $1.1B and net income of -$446M, a net margin of -41.2%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (1/5).
Key numbers: a price to free cash flow of 14.1, 5-year revenue growth of 18% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 86% below the current price.
Score: 1.6 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.2B | $1.2B | $1.1B | $1.2B | $932M | $522M | $253M |
| Net income | -$446M | -$116M | -$155M | -$527M | -$253M | $17M | $63M | $53M |
| Free cash flow | $132M | $229M | $149M | $162M | -$142M | -$263M | -$298000 | -$53M |
| EPS (diluted) | $-2.31 | $-0.58 | $-0.79 | $-2.28 | $-0.95 | $0.21 | $0.53 | $0.46 |
| Net margin | -41.2% | -9.8% | -13.1% | -46.7% | -20.8% | 1.9% | 12.1% | 21.0% |
| ROIC | — | 8.1% | 4.4% | -9.3% | 1.5% | 5.9% | 35.5% | 43.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $18.32, 68% above the current price; targets range from $15.00 to $22.00; the consensus rating is “Strong buy”; expected EPS is $-2.01 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Trulieve Cannabis stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 86% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Trulieve Cannabis pay a dividend?
Not currently.
Is Trulieve Cannabis a good stock to buy?
We do not give buy or sell advice. Trulieve Cannabis scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.